An interventional study of Knee Extension Brace (Zimmer-type) and Early Mobilization (Standard Care) in Total Knee Arthroplasty, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 190 studies in Pain, Postoperative with a site in Canada — 38 open to participants now, 42 under way, 3 of them phase 3. Pain, Postoperative · Canada.
Among the 190 studies in Pain, Postoperative with a site in Canada, this one is the 62nd largest by planned enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2026, is one of 94 with no phase, reaches primary completion later than 35 of the 41 other live ones, and was the 189th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →38 of the 190 studies in Pain, Postoperative with a site in Canada are open now. Recruiting first, the newest first:
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Université de Sherbrooke · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
190 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 17 · Phase 3 22 · Phase 4 38
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 106 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 82 across the 175 interventional studies, 140 across the 15 observational. Of the 125 that completed or were terminated, 8 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 190 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 4 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
13 of the studies in Pain, Postoperative with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT06324942University of CalgaryAnalgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section. | 2026-12 |
| NCT06276257CHU de Quebec-Universite LavalParavertebral Block for Mastectomy With Immediate Reconstruction | 2026-12 |
| NCT03675386University Health Network, TorontoReducing Opioid Use for Chronic Pain Patients Following Surgery | 2026-12-31 |
| NCT05722002University of MichiganComparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial | 2027-02-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 190 studies in Pain, Postoperative with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative pain following total knee arthroplasty (TKA) is often difficult to manage, particularly with the increasing use of outpatient surgery where patients recover at home. This study aims to evaluate whether wearing a knee extension brace for the first 72 hours after surgery can reduce pain and improve recovery.
This pilot randomized controlled trial will compare two groups of patients undergoing primary unilateral TKA: one group will wear an extension brace continuously for 72 hours after surgery, while the control group will follow standard care with early mobilization. Participants will be followed for up to 12 months.
The primary objective of this pilot study is to assess the feasibility of conducting a larger trial, including recruitment rates, adherence to the intervention, follow-up completion, safety, and acceptability. Clinical outcomes will also be explored, including pain at 2 and 6 weeks after surgery (measured using a visual analog scale), knee function, range of motion, opioid consumption, complications, healthcare use, and quality of life.
The study hypothesizes that short-term immobilization of the knee in full extension will reduce postoperative pain and may improve early recovery outcomes. Findings from this pilot study will inform the design of a larger definitive trial and may contribute to improving postoperative care and pain management after knee replacement surgery.
Postoperative pain following total knee arthroplasty (TKA) remains a significant clinical challenge, particularly in the context of increasing use of outpatient surgical pathways. Optimizing early postoperative pain management is essential to improve recovery, reduce unplanned healthcare utilization, and support enhanced recovery after surgery (ERAS) principles.
This study aims to evaluate the effect of short-term postoperative immobilization using a knee extension brace (Zimmer-type) worn continuously for 72 hours following primary unilateral TKA on postoperative pain at 2 and 6 weeks, measured using the Visual Analog Scale (VAS). The study hypothesizes that maintaining the knee in full extension during the immediate postoperative period will reduce pain and improve early recovery outcomes.
Study Design
This study is a pilot randomized controlled trial with a 1:1 allocation ratio and a single-blind design, in which outcome assessors are blinded to group allocation. The study is conducted at a single center (CHUS, Estrie, Canada).
Participants undergoing primary unilateral TKA will be randomized into one of two groups:
Intervention group: immobilization of the operated knee in full extension using a Zimmer-type brace for 72 hours postoperatively, followed by standard physiotherapy care.
Control group (standard of care): no restriction in movement, with early supervised mobilization according to usual physiotherapy practice.
The study adopts a pragmatic approach, allowing variability in physiotherapy delivery to reflect real-world clinical practice and enhance external validity. Timing and frequency of physiotherapy sessions will be recorded.
Study Objectives
The primary objective of this pilot study is to assess feasibility, including:
Recruitment rate and participant flow (inclusion, exclusion, refusal) Follow-up completion rate (target ≥80%) Intervention adherence (target ≥80% compliance in the intervention group) Safety, based on postoperative complication rates (including deep vein thrombosis, wound complications, and joint stiffness) Acceptability of the intervention and study procedures among patients and healthcare providers Estimation of variance in VAS pain scores to inform sample size calculation for a future definitive trial
The clinical primary outcome is postoperative pain at 2 and 6 weeks measured using the VAS, reported as mean differences between groups with 95% confidence intervals.
Secondary clinical outcomes include:
Knee range of motion (ROM) Postoperative opioid consumption Postoperative complications Emergency department visits and hospital readmissions Health-related quality of life (EQ-5D-5L) Knee function (Knee Society Score [KSS] and Functional KSS) Blood loss (hemoglobin levels) Postoperative inflammation (C-reactive protein) Study Population
The study population includes adults aged 18 years and older undergoing primary unilateral TKA for knee osteoarthritis at CHUS.
Key exclusion criteria include:
Known thrombophilia or bleeding disorders History of thromboembolic events Contraindications to brace use (e.g., material allergy) Revision or constrained knee prostheses Use of continuous postoperative nerve block infusion Sample Size
The pilot study aims to recruit 106 participants (53 per group) over an 18-month period, representing approximately 15% of the estimated sample size required for a definitive trial. Data from this pilot will be used to refine sample size calculations.
Recruitment and Procedures
Eligible patients will be identified during orthopedic consultations and approached for participation. After informed consent, baseline data (demographics, clinical characteristics, and preoperative measures) will be collected.
Randomization will occur on the day of surgery. The intervention will be applied by the orthopedic surgeon.
Follow-up assessments will occur at:
2-5 days postoperatively 2 weeks 6 weeks 3 months 12 months
Data collected include patient-reported outcomes, clinical assessments, laboratory values, and healthcare utilization. Participants in the intervention group will record brace wear time and opioid consumption using daily logs.
Data Collection and Outcomes
Pain will be assessed using the Visual Analog Scale (VAS). Additional outcomes include ROM measured with a goniometer, validated questionnaires (KSS, FKSS, EQ-5D-5L), laboratory markers (hemoglobin and C-reactive protein), and postoperative complications.
Opioid consumption and brace adherence will be self-reported using patient diaries. Healthcare utilization (emergency visits and readmissions) will be collected retrospectively.
Data Analysis
Feasibility outcomes will be analyzed descriptively using an intention-to-treat approach. Recruitment, adherence, and completion rates will be reported with 95% confidence intervals.
Comparisons between groups for exploratory clinical outcomes will be conducted using appropriate statistical tests depending on data distribution. This pilot study is not powered for definitive efficacy conclusions but will provide estimates to guide a larger trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo postoperative immobilization of the operated knee in full extension using a Zimmer-type knee brace for 72 hours following primary total knee arthroplasty, followed by standard physiotherapy care.
Device: Knee Extension Brace (Zimmer-type)
Participants will receive standard postoperative care consisting of early mobilization without movement restriction and supervised physiotherapy according to usual clinical practice.
Other: Early Mobilization (Standard Care)
Participants will wear a knee extension brace maintaining the operated knee in full extension for 72 hours following surgery. The brace is to be worn continuously (target ≥23 hours per day), after which standard physiotherapy care will be initiated.
Participants will receive standard postoperative care, including early mobilization without restriction and supervised physiotherapy according to usual clinical practice.
Study feasibility
Feasibility will be assessed by recruitment rate, follow-up completion (target ≥80%), intervention adherence (target ≥80%), and safety based on postoperative complications.
Time frame: Up to 18 months (study completion)
Postoperative Pain (VAS)
Pain measured using a 100-mm Visual Analog Scale.
Time frame: 2 weeks, 6 weeks, 3 months, 12 months
Knee Range of Motion (ROM)
Measured with a goniometer.
Time frame: 2 weeks, 6 weeks, 3 months, 12 months
Opioid Consumption
Self-reported number of tablets consumed.
Time frame: Up to 6 weeks
Postoperative Complications
Includes wound complications, infection, and thromboembolic events.
Time frame: Up to 6 weeks
Healthcare Utilization
Emergency visits and hospital readmissions.
Time frame: Up to 6 weeks
Quality of Life (EQ-5D-5L)
Standardized questionnaire.
Time frame: Baseline, 2 weeks, 6 weeks, 3 months, 12 months
Knee Function (KSS/FKSS)
Validated functional scores.
Time frame: Baseline, 6 weeks, 3 months, 12 months
Inflammation (CRP)
2-5 days, 2 and 6 weeks
Time frame: Blood test marker.
Hemoglobin
Blood test.
Time frame: 2-5 days and 6 weeks
Global Improvement (PGI-C)
Patient-reported change.
Time frame: 2 and 6 weeks
Brace Compliance
Self-reported hours of wear.
Time frame: First 72 hours
Perceived Safety
Study-specific questionnaire.
Time frame: 2 weeks
Plan to share: Yes — De-identified individual participant data (IPD) will be made available upon reasonable request to the corresponding investigator.
Time frame: Data will be available beginning 6 months following publication of the primary results and ending 5 years after publication.
Access criteria: Access will be granted to researchers who provide a methodologically sound proposal. Requests will be reviewed by the study team, and data sharing will require a data use agreement.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 21 months is above that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.